Dementia is a common chronic condition, with predicted increasing prevalence. Nearly all
patients with dementia will experience neuropsychiatric symptoms (NPS). This causes
significant burden for the individual patients and their caregivers. Current treatment has
only modest efficacy and important side-effects. Formulations with Δ9-tetrahydrocannabinol
(THC), the psycho-active compound of cannabis, are currently being registered for spasms in
multiple sclerosis and other diseases, and may have beneficial effects on NPS.